The Lymphoma Channel is supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ASH 2020 | Key updates in lymphoma from ASH 2020
Paolo Strati, MD, The University of Texas MD Anderson Cancer Center, Houston, TX, shares his highlights from ASH 2020, picking out a presentation of early data from the TRANSCEND-NHL-001 study (NCT02631044) investigating the safety and efficacy of lisocabtagene maraleucel for relapsed/refractory mantle cell lymphoma (MCL) and a Phase II study (NCT03618550) investigating a novel combination of pembrolizumab plus gemcitabine, vinorelbine and liposomal doxorubicin for relapsed/refractory Hodgkin lymphoma. This interview took place during the 62nd American Society of Hematology (ASH) Annual Meeting and Exposition, 2020.
